A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
Hackensack Meridian Health
American Society of Clinical Oncology
Canadian Cancer Trials Group
Baylor College of Medicine
Dana-Farber Cancer Institute
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
CytomX Therapeutics
M.D. Anderson Cancer Center
Intensity Therapeutics, Inc.
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Stanford University
National Cancer Institute (NCI)
Chinese PLA General Hospital
Icahn School of Medicine at Mount Sinai
Chinook Therapeutics, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Stanford University
Lytix Biopharma AS
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)